Cannabis Biopharma Avicanna Reports Revenue Growth In Q3 Amid Rising Net Loss

CBD-focused company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Friday its third-quarter financial results.

“Q3 reflects the continued progress of our strategy to build a diversified and sustainable biopharmaceutical business,” Aras Azadian, the company’s CEO, said. “We are pleased with the impact of our medical affairs initiatives and the strengthened engagement within the Canadian medical community, which have contributed to consecutive quarters of revenue growth in Canada.”

Q3 2025 Financial Highlights

• Total revenue amounted to CA$6.4 million ($4.56 million) compared to CA$6.3 million in the prior year’s period.
• Gross profit totaled CA$3.1 million, down from CA$3.6 million in the prior year’s period.
• Net loss grew to CA$1.4 million, from CA$786,388 in the third quarter of fiscal 2024.
• Total expenses totaled CA$4.5 million, up from CA$4.3 million in the corresponding period of last year.
• Adjusted EBITDA came in negative at CA$0.79 million, marking a decrease over the respective three-month period in 2024.

Avicanna is a biopharmaceutical company that focuses on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products.